Ethypharm Corp, 1500 Market St, Philadelphia, PA 19102, US

Spirovant Sciences, Inc is a gene therapy company based in Philadelphia, PA that is dedicated to revolutionizing the treatment of respiratory diseases, including cystic fibrosis. They design novel therapies using their proprietary Adeno-Associated Virus (AAV) platform, which consists of an optimized transgene payload, a novel AAV capsid, and an augmenter to drive high expression of the functional cystic fibrosis transmembrane conductance regulator (CFTR) protein in human airway epithelia. Under the leadership of Chief Executive Officer Joan Lau, PhD, MBA, Spirovant has gained prestigious scientific support from the Cystic Fibrosis Foundation and has been acquired twice in one year, most recently by Sumitomo Pharma. With a team of award-winning experts, including Chief Medical Advisor Eric Yuen, MD, and Chief Scientific Officer Roland Kolbeck, PhD, Spirovant is at the forefront of developing advanced gene therapies to address the unmet needs of patients with respiratory diseases.Generated from the website

IV Incorporated

Naveh, Marcia S MD

S-Clinica

The Knowledge Academy